7459 — Medipal Holdings Balance Sheet
0.000.00%
- ¥494bn
- ¥371bn
- ¥4tn
- 85
- 89
- 81
- 98
Annual balance sheet for Medipal Holdings, fiscal year end - March 31st, JPY millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | C2023 March 31st | 2024 March 31st | 2025 March 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Yuho | Yuho | Yuho | Yuho | Tanshin |
Standards: | JAS | JAS | JAS | JAS | — |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 241,517 | 261,920 | 195,031 | 230,470 | 261,407 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 766,855 | 774,684 | 797,179 | 824,471 | 830,324 |
Total Inventory | |||||
Total Other Current Assets | |||||
Total Current Assets | 1,174,113 | 1,209,766 | 1,179,280 | 1,244,190 | 1,282,746 |
Net Property, Plant And Equipment | 261,588 | 264,374 | 268,363 | 270,953 | 268,564 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 1,679,934 | 1,709,474 | 1,709,658 | 1,799,127 | 1,824,984 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 952,835 | 1,008,816 | 971,519 | 1,007,719 | 1,009,447 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 1,156,920 | 1,179,169 | 1,148,300 | 1,198,778 | 1,205,418 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 523,014 | 530,305 | 561,358 | 600,349 | 619,566 |
Total Liabilities & Shareholders' Equity | 1,679,934 | 1,709,474 | 1,709,658 | 1,799,127 | 1,824,984 |
Total Common Shares Outstanding |